This study describes an exceptional, alternative pathway of SCLC pathogenesis via chromothripsis and ecDNA in the absence of RB1 and TP53 mutations or smoking mutagenesis, defining a novel tumor type associated with distinct prognosis and therapeutic profile. This evidence concerns the gene RB1 and neoplasm.